BD puts Clontech on the block
Becton Dickinson is planning to sell of its Clontech molecular biology business, five years after purchasing it for $200 million.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Becton Dickinson is planning to sell of its Clontech molecular biology business, five years after purchasing it for $200 million.